ACN Newswire
Read More

Asia Pacific Cell & Gene Research: Novotech is Growing 50% Faster than ROW

indie
3 minutes

SYDNEY, AU, Feb 3, 2023 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award, said the number of cell & gene therapy trials in the region was growing 50% faster than ROW. The majority of trials are in oncology, specifically for blood cancers, viral infections, and solid tumors.Novotech, which has extensive experience in cell & gene therapy clinical trials, is sponsoring the 6th Annual Cell And Gene Therapy Innovation Summit in Berlin, Germany (15-16 February 2023).The company recently acquired EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. The acquisition is part of Novotech's global expansion program in Europe and the US.The acquisition means biotech clients can access Novotech's unique and unparalleled suite of early to late-phase CRO services across Europe and the US, with a specialist focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials. The latest data shows Asia Pacific is t...

ACN Newswire
Read More

Novotech presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference

indie
3 minutes

SYDNEY, AU, Sep 15, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Cell & Gene Therapy Clinical Trials award at the 6th Cell & Gene Therapy World Asia 2022 conference.Novotech has extensive experience in cell & gene therapy clinical trials across Asia Pacific. The Asia Pacific accounts for over a third of cell & gene therapy trial activity with China being the leading location in APAC. In addition, APAC has nearly a 50% faster growth rate in cell & gene therapy trials than ROW. Blood cancers (ALL, NHL, DLBCL, lymphomas), solid tumors, viral infections, liver and gastrointestinal tract cancers are the top indications in China-based cell & gene therapy trials between 2016 and 2021.Watch our recent Endpoints News webinar for more information:EVOLUTION OF CELL & GENE THERAPY IN CHINA: THE CASE FOR UNIVERSAL CAR-Thttps://novotech-cro.com/webinars/evolution-cell-gene-therapy-china-case-universal-car-tThe award was presented to Novotech during the 6th Cell & Gene Therapy World Asia 2022 conference (14th - 15th September) at the Sheraton Towers, Singapore.Novotech CEO Dr. John Moller ...

JCN Newswire
Read More

Hitachi: Proton Therapy Provider Chosen for UW Health Eastpark Medical Center

ruth
3 minutes

MADISON, WI, Jul 27, 2022 - (JCN Newswire via SEAPRWire.com) - UW Health has selected Hitachi, Ltd. (TSE:6501, "Hitachi") to provide the infrastructure to support proton therapy at UW Health Eastpark Medical Center.Proton therapy equipment combined with Hitachi's 360° rotating gantry and Leo's upright systemHitachi will provide equipment and technology to support UW Health's traditional proton therapy room equipped with spot scanning irradiation technology, a 360 degrees rotating gantry with cone-beam CT(1), and Real-time image Gated Proton Therapy (RGPT)(2), as well as the revolutionary upright proton therapy coming to UW Health from Leo Cancer Care, according to Dr. Paul Harari, radiation oncologist, UW Health, and chair of the Department of Human Oncology, University of Wisconsin School of Medicine and Public Health."We're excited to reach this important milestone to offer state-of-the-art proton therapy at UW Health," Harari said. "It's particularly significant in linking together Hitachi, an experienced proton provider, a new technology from Leo Cancer Care and a major academic medical center with a track record of cutting-edge technology development and implementation, all wo...

JCN Newswire
Read More

Shonan Kamakura Advanced Medical Center Begins Treatment with Hitachi’s First Dedicated Compact Proton Therapy System

ruth
4 minutes

TOKYO, Feb 2, 2022 - (JCN Newswire via SEAPRWire.com) - Hitachi, Ltd. (TSE: 6501) has announced that "Shonan Kamakura Advanced Medical Center" at Shonan Kamakura General Hospital of Tokushukai Medical Group, where Hitachi's compact proton therapy system (hereafter, "the system") has been installed, has commenced treatment with the system on 31 January 2022. This is the first order for Hitachi's dedicated compact proton therapy system.Proton Therapy SystemShonan Kamakura Advanced Medical Center is a medical facility providing comprehensive cancer treatment, including advanced radiotherapy, built adjacent to the site of Shonan Kamakura General Hospital by Tokushukai Group Medical Corporation, which operates approximately 400 medical facilities and nursing homes throughout Japan. Until now, there have been no proton therapy facilities in Kanagawa Prefecture, where the center is located, but the compact proton therapy system, with its reduced footprint, makes it possible to install a proton therapy facility on a limited site close to the city center.Features of the installed systemIn response to the growing worldwide demand for smaller proton therapy systems, Hitachi has developed the ...

JCN Newswire
Read More

Hitachi Selected by the University of Tsukuba for its Second Proton Therapy System as a PFI Project

ruth
4 minutes

TOKYO, Nov 22, 2021 - (JCN Newswire via SEAPRWire.com) - Hitachi, Ltd. (TSE: 6501) announced today that it has been selected by the University of Tsukuba to provide Hitachi's proton therapy solution including its design, manufacturing, construction, maintenance and operation as a PFI (Private Finance Initiative) project*. The parties have signed the contract on September 30, 2021. The new proton therapy center will be equipped with Hitachi's compact design proton therapy system, including a set of one accelerator and two rotating gantry treatment rooms. The new therapy center is expected to start treating patients around the summer of 2025, followed by a 20-year period of operation and maintenance support by Hitachi.Image of New Proton Therapy Center; The new center is on the left of existing siteThe University of Tsukuba has been using Hitachi's proton therapy system since 2001. After 20 years of operation, due to aging facilities, the university has determined to introduce a 2nd unit. Upon completion and opening of the new proton therapy center, the University of Tsukuba will shift its treatment from the existing center to the new center. This is the first time in Japan for a par...

ACN Newswire
Read More

Topelia Australia launches US$25M Series A call for COVID-19 ATT Ziverdox

indie
3 minutes

SYDNEY, Oct 14, 2021 - (ACN Newswire via SEAPRWire.com) - Topelia Australia, a biotech company established to commercialise a novel ATT treatment for Australians in quarantine, has launched an investment program designed to keep the invention Australian owned - while rolling out treatment to the world.Prof Thomas Borody- Topelia announces US$25 mil Series A capital raise to fund manufacture and clinical trials of the COVID-19 Antiviral Triple Therapy (ATT).- Topelia has secured exclusive global patent rights to COVID-19 Antiviral Triple Therapy from Prof Thomas Borody.- Borody's track record includes effective treatment for Peptic Ulcers & Crohn's Disease, recolonisation of bowel microbiome, and 3 FDA approved drugs on the market.- Based on current research, the ATT provides an inexpensive and medically efficacious treatment for the prevention and early treatment of COVID-19.The company is raising USD$25 million from investors in Australia, Asia and USA. The company said: "Topelia proposes to offer the ATT treatment alongside the current vaccination program to treat and vaccinate our way out of this pandemic. As Australia comes out of lockdowns and countries around the world ex...

JCN Newswire
Read More

Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)

ruth
2 minutes

TOKYO, Jun 24, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer's disease (AD). Breakthrough Therapy designation is an FDA program intended to expedite the development and review of medicines for serious or life-threatening conditions. The benefits of a Breakthrough Therapy designation include more intensive guidance on an efficient development program as well as eligibility for rolling review and potentially priority review. The FDA's Breakthrough Therapy designation for lecanemab is based on the recently published results of a Phase 2b clinical trial (Study 201) of 856 patients with mild cognitive impairment (MCI) due to AD and mild AD with confirmed presence of amyloid pathology.1 The proof-of-concept Study 201 explored the impact of treatment with lecanemab on reducing brain amyloid beta (Abeta) and clinical decline. In this study, pre-specified analysis showed consistent reduction of clinical decline across several clinical a...